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Abstract
Aim: To	analyse	incidence,	treatment	and	outcomes	of	paediatric	liver	malignancies	
in	Finland	during	1987‐2017.
Methods: Medical	records	and	national	cancer	registry	data	of	47	children	with	liver	
malignancies	were	reviewed.	Survival	was	calculated	with	the	Kaplan‐Meier	method.
Results: During	 follow‐up,	 liver	 malignancy	 incidence	 remained	 stable	 at	 1.1:106. 
Altogether,	 42	 patients	 with	 hepatoblastoma	 (n	 =	 24),	 hepatocellular	 carcinoma	
(n	=	11)	and	undifferentiated	embryonal	sarcoma	(n	=	7)	underwent	surgery	at	me‐
dian	age	4.6	(interquartile	range,	2.0‐9.6)	years	and	were	followed	up	for	13	(7.0‐19)	
years.	Cumulative	5‐year	survival	was	86%	for	hepatoblastoma,	41%	for	hepatocel‐
lular	 carcinoma	 and	 67%	 for	 undifferentiated	 embryonal	 sarcoma.	 Five‐year	 sur‐
vival	was	decreased	among	hepatoblastoma	patients	aged	≥	2.4	years	(73%	versus	
100%,	P	=	.040),	with	PRETreatment	EXTent	of	disease	IV	(PRETEXT,	60%	vs	100%,	
P	=	.004),	and	with	recurrent	disease	(67%	vs	88%,	P	=	.029).	Recurrent/residual	dis‐
ease	associated	with	decreased	5‐year	survival	 in	hepatocellular	carcinoma	(0%	vs	
83%,	P	=	.028).	Survival	was	similar	among	19	transplanted	and	23	resected	patients.	
In	total,	14	deaths	occurred	either	for	the	underlying	malignancy	(n	=	8),	adverse	ef‐
fects	of	chemotherapy	(n	=	5)	or	unrelated	reasons	(n	=	1).
Conclusion: Outcomes	for	PRETEXT	I‐III	hepatoblastoma	and	un‐metastasized	hepa‐
tocellular	 carcinoma	 were	 encouraging.	 Adverse	 effects	 of	 chemotherapy	 signifi‐
cantly	contributed	to	mortality.
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1  | INTRODUC TION
Malignant	liver	tumours	are	the	third	most	common	abdominal	ma‐
lignancy	 among	 children,	 accounting	 for	 approximately	 1%	 of	 all	
childhood	solid	tumours.1	The	most	common	paediatric	liver	cancer	
is	hepatoblastoma	(HB)	with	an	incidence	of	1.5	cases	per	million	per	
year.2	 Survival	 rates	 for	HB	have	 improved	drastically	 since	 intro‐
duction	of	cisplatin‐based	chemotherapy	regimens	combined	to	sur‐
gery,	and	currently	approach	70%‐90%	at	5	years.3	Hepatocellular	
carcinoma	(HCC)	is	the	second	most	common	malignant	liver	tumour	
in	children	and	much	less	responsive	to	chemotherapy	with	lower	5‐
year	survival	 rates	varying	between	50%‐65%.4‐6	Undifferentiated	
embryonal	sarcoma	is	a	rare	liver	malignancy	sharing	features	with	
benign	 mesenchymal	 hamartoma.	 After	 complete	 resection,	 non‐
metastatic‐undifferentiated	 embryonal	 sarcoma	 has	 an	 excellent	
prognosis	in	children.7
Neoadjuvant	 chemotherapy	 followed	 by	 surgical	 resection	 or	
liver	 transplantation	 has	 been	 the	 cornerstone	 of	 childhood	 liver	
malignancy	treatment,	although	very	low‐risk	tumours	can	be	safely	
managed	 with	 upfront	 surgery.2,8	 Unfortunately,	 the	 majority	 of	
patients	 present	with	more	 advanced	 disease,	 and	 approximately,	
15%	of	patients	with	HB	and	20‐35%	of	patients	with	HCC	have	a	
metastasized	disease	at	diagnosis.2,5,6	While	chemotherapy	in	most	
cases	renders	extended	HB	suitable	for	resection	or	liver	transplan‐
tation,	 HCC	 with	 extrahepatic	 disease	 extension	 usually	 remains	
beyond	 curative	 treatment.	 The	 international	 multicentre	 studies	
ran	by	cooperative	trial	groups	have	increased	our	understanding	on	
the	risk‐stratification,	optimal	chemotherapy	protocols	and	surgical	
approach	for	malignant	 liver	tumours.2,9,10	Histologic	subtype,	age,	
preoperative	 alpha‐fetoprotein	 level,	 presence	 of	 metastases	 and	
radiological	PRETEXT	(PRETreatment	EXTent	of	disease)	staging	are	
essential	determinants	of	prognosis.10
Although	 large	 multicentre	 trials	 have	 improved	 and	 system‐
atised	 management	 of	 paediatric	 liver	 malignancies,	 single‐centre	
studies	are	also	noteworthy	in	providing	long‐term	follow‐up	data	on	
surgical	outcomes,	adverse	effects	of	chemotherapy	and	other	con‐
sequences	of	the	treatment,	including	growth	impairment.11,12	The	
incidence	of	HB	appears	 to	be	 increasing,13	 and	population‐based	
studies	 are	 needed	 to	 understand	 the	 epidemiology	 of	 paediatric	
malignancies.	 By	 combining	 reliable	 national	 cancer	 registry	 data	
with	 the	 hospital	 records,	 we	 evaluated	 the	 incidence,	 treatment	
outcomes	and	long‐term	follow‐up	results	for	childhood	hepatic	ma‐
lignancies	in	all	of	Finland.
2  | METHODS
2.1 | Patients and data collection
Helsinki	 University	 Hospital	 is	 a	 nationwide	 referral	 centre	 for	
paediatric	liver	malignancies	in	all	of	Finland	with	paediatric	liver	
transplantation	programme	since	1987.	All	Finnish	children	under	
age	of	18	years	at	diagnosis	with	malignant	liver	tumours	between	
1987	and	2016	were	 included.	We	obtained	definitive	diagnosis,	
tumour	 histology,	 cancer	 stage,	 recurrence	 and	 survival	 data	
from	 the	 nationwide	 Finnish	 Cancer	 Registry,	 which	 maintains	
records	 of	 all	 the	 cancer	 patients	 from	 every	medical	 facility	 in	
Finland.	The	Finnish	Cancer	Registry	practically	covers	the	popu‐
lation	 completely	 and	 has	 high	 accuracy.14	 Retrospectively	 col‐
lected	data	from	the	medical	patient	records	included	associated	
diseases,	 imaging	 findings,	 histology	 reports,	 alpha‐fetoprotein	
levels,	 details	 of	 oncological	 and	 surgical	 management,	 adverse	
effects	 and	 surgical	 complications.	 In	 addition,	 height,	 weight	
and	 liver	 biochemistry	 were	 recorded	 at	 last	 follow‐up.	 Causes	
of	 death	were	 confirmed	 from	 death	 certificates	 obtained	 from	
Statistics	Finland.	Malignancies	diagnosed	among	the	first‐degree	
relatives	of	all	patients	and	age‐gender	matched	controls	were	re‐
corded	from	the	Finnish	Cancer	Registry.	Normal	population	con‐
trols	(five	per	patient)	were	collected	from	the	Finnish	Population	
Register	Centre.
2.2 | Radiological staging and histology
All	patients	underwent	pretreatment	computed	tomography	(CT)	
and/or	magnetic	 resonance	 imaging	 (MRI).	 An	 experienced	 pae‐
diatric	radiologist	blinded	to	clinical	data	reassessed	the	 imaging	
findings	retrospectively	according	to	PRETEXT	staging.10 In addi‐
tion,	patients	with	HCC	were	classified	by	Milan	and	University	of	
California	San	Francisco	criteria.15,16	Preoperative	imaging	was	un‐
available	for	one	patient.	Tumour	histology	was	based	on	the	most	
representative	 specimen	 analysed	 by	 experienced	 liver	 patholo‐
gists.	In	HB,	small	cell‐undifferentiated	tumours	were	considered	
to	represent	high‐risk	histology,	foetal	subtypes	were	defined	as	
low‐risk	histology	and	other	tumour	subtypes	as	intermediate‐risk	
histology.2	HCC	histology	was	divided	into	fibrolamellar	and	other	
subtypes.
2.3 | Chemotherapy
As	shown	in	Table	1,	patients	with	HB	were	mainly	treated	according	
to	SIOPEL‐2	and	‐4	protocols	or	by	other	cisplatin‐doxorubicin–based	
combinations.17,18	 Patients	 with	 HCC	 received	 cisplatin‐doxoru‐
bicin–based	chemotherapy	with	or	without	sorafenib.	Patients	with	
undifferentiated	 embryonal	 sarcoma	 were	 treated	 by	 ifosfamide‐
vincristine–based	neoadjuvant	chemotherapy.
Key notes
•	 Incidence	of	paediatric	liver	malignancies	remained	sta‐
ble	over	a	30‐year	follow‐up.
•	 Improved	treatment	strategies	are	needed	for	PRETEXT	
IV	 hepatoblastoma	 and	 metastasized	 hepatocellular	
carcinoma.
•	 Adverse	 effect	 of	 chemotherapy	 significantly	 contrib‐
uted	to	mortality.
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2.4 | Surgical treatment
Primary	liver	resections	were	mostly	anatomical.	Patients	deemed	
unsuitable	 for	 curative	 resection	 due	 to	 local	 extension,	 central	
tumour	location	or	vascular	invasion	were	evaluated	as	liver	trans‐
plantation	 candidates.	 Unlike	 lung	 metastases	 in	 HB	 resolving	
after	 surgical	 resection	 or	 chemotherapy,	 any	 extrahepatic	HCC	
was	 considered	 as	 a	 contraindication	 for	 liver	 transplantation.	
Rescue	 liver	 transplantation	was	 considered	 in	 case	 of	 local	 re‐
currence	or	residual	disease	after	primary	resection	when	no	dis‐
tant	 metastases	 were	 observed.	 Grafts	 for	 liver	 transplantation	
were	harvested	from	deceased	donors.	Immunosuppression	after	
liver	 transplantation	 consisted	 of	 cyclosporine,	 azathioprine	 and	
low‐dose	methylprednisolone.	During	the	last	decade,	major	liver	
resections	were	performed	in	cooperation	with	adult	 liver/trans‐
plant	surgeons,	who	also	performed	harvesting	and	reductions	of	
liver	grafts.
2.5 | Statistical methods
Continuous	 data	 are	 expressed	 as	 medians	 with	 interquartile	
ranges	and	categorical	data	as	frequencies	unless	otherwise	stated.	
Differences	between	groups	were	assessed	with	the	chi‐square	or	
Fisher's	exact	test	for	categorical	variables	and	the	Mann‐Whitney	U 
test	for	continuous	variables.	The	incidence	of	malignant	paediatric	
liver	tumours	in	Finland	was	estimated	by	relating	the	number	of	di‐
agnosed	patients	to	the	number	of	children	at	risk	(aged	≤	18	years)	
over	 the	 same	 time	period.19	 Incidence	 rate	was	expressed	as	 the	
number	of	new	cases/person	years	at	risk	over	5‐year	time	periods.20 
Linear	regression	was	used	to	analyse	the	observed	change	in	inci‐
dence	rate	over	follow‐up	time.	The	cumulative	overall	survival	and	
disease‐free	survival	rates	were	defined	with	Kaplan‐Meier	survival	
analyses,	and	the	log‐rank	test	was	used	to	analyse	differences	be‐
tween	subgroups.	Patients	who	received	rescue	liver	transplantation	
were	 analysed	 in	 the	 liver	 transplantation	 group	 unless	 otherwise	
TA B L E  1  Characteristics	of	surgically	treated	patients	according	to	liver	tumour	types
 All patients, n = 42 HB, n = 24 HCC, n = 11 UES, n = 7
Boys,	n	(%) 20	(48) 13	(54) 5	(46) 2	(29)
Age	at	diagnosis,	years 3.5	(1.6‐8.3) 1.7	(0.85‐3.3) 11	(8.3‐14) 5.2	(2.7‐6.6)
AFP	at	diagnosis,	kU/la  49	000	(440‐180	000) 110	000	(59	000‐370	000) 3000	(250‐32	000) 1.0	(1.0‐64)
AFP	at	time	of	primary	surgery,	
kU/lb
150	(9‐2100) 130	(17‐1000) 270	(3‐2400) 1.0	(1.0‐1.0)
PRETEXT,	n	(%)c
I 1	(2.3) 0	(‐) 1	(9.1) 0	(‐)
II 20	(48) 9	(38) 7	(64) 4	(57)
III 11	(26) 7	(29) 2	(18) 2	(29)
IV 9	(21) 8	(33) 1	(9.1) 0	(‐)
Extrahepatic	disease	at	diagnosis,	
n	(%)
14	(33) 7	(29) 4	(36) 2	(29)
Distant	metastases 8	(19) 3	(13) 3	(27) 1	(14)
Neoadjuvant	chemotherapy
Cisplatin‐doxorubicin‐based	
combinations
30	(71) 23	(96) 7	(64) 0	(‐)
Cisplatin‐doxorubicin‐sorafenib 3	(7.1) 0	(‐) 3	(27) 0	(‐)
Ifosfamide‐vincristine‐based	
combinations
6	(14) 0	(‐) 0	(‐) 6	(86)
Doxorubicin‐vincristine 1	(2.3) 0	(‐) 0	(‐) 1	(14)
No	chemotherapy 2	(4.8) 1	(4.2) 1	(9.1) 0	(‐)
Definitive	surgical	management,	n	(%)
Resection 23	(55) 10	(42) 6	(55) 7	(100)
LT 13	(31) 9	(37) 4	(36) 0
Rescue	LT 6	(14) 5	(21) 1	(9.1) 0
Abbreviations:	AFP,	alpha‐fetoprotein;	HB,	hepatoblastoma;	HCC,	hepatocellular	carcinoma;	LT,	liver	transplantation;	UES,	undefined	embryonal	
sarcoma.
aAFP	at	diagnosis	missing	for	nine	patients.	
bAFP	at	time	of	surgery	missing	for	eight	patients.	
cPRETEXT	stage	missing	for	one	patient.	
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stated.	A	two‐sided	P‐value	of	<.05	was	considered	statistically	sig‐
nificant.	Data	analysis	was	performed	using	SPSS	Statistics	version	
24.0	(IBM	Corp,	New	York,	USA).
2.6 | Ethics
The	 study	 protocol	 was	 approved	 by	 the	 Helsinki	 University	
Hospital's	ethical	committee	as	well	as	by	the	National	Institute	of	
Health	and	Welfare.
3  | RESULTS
3.1 | Epidemiology of childhood liver malignancies 
in Finland
Out	of	the	47	malignant	liver	tumours	diagnosed	in	47	patients	dur‐
ing	the	study	period,	27	(57%)	were	HB,	13	(28%)	HCC	and	7	(15%)	
undifferentiated	 embryonal	 sarcoma.	 Their	 incidence	 showed	 no	
significant	change	over	time	(Figure	S1).	Median	incidence	rate	of	
all	 liver	malignancies	as	well	as	HB	was	1.1:106	and	0.66:106 dur‐
ing	the	whole	follow‐up	period	while	1.3:106	and	0.66:106	during	
the	 latest	5‐year	time	period,	respectively	 (Figure	S1).	The	occur‐
rence	of	malignancies	among	the	first‐degree	relatives	of	 the	pa‐
tients	showed	no	difference	when	compared	with	cancer	incidence	
in	 first‐degree	 relatives	of	 age‐gender	matched	controls	 (4.6%	vs	
4.3%,	P	=	.850).
3.2 | Patient characteristics
Four	patients	with	metastatic	disease	 (HB,	n	=	3;	HCC,	n	=	1)	 re‐
ceived	chemotherapy	and	died	without	surgery.	In	addition,	one	pa‐
tient	was	deemed	inoperable	due	to	large	extrahepatically	extended	
HCC	with	 vascular	 invasion	 and	extensive	portal	 vein	 thrombosis.	
Including	 the	 unoperated	 patients,	 the	 cumulative	 overall	 5‐year	
TA B L E  2  Comparison	of	HB	and	HCC	patients	managed	with	liver	transplantation	or	liver	resection
 
HB, n = 24 HCC, n = 11
Transplantation, n = 14 Resection, n = 10 Transplantation, n = 5 Resection, n = 6
Age	at	diagnosis,	years 2.1	(1.5‐4.1) 1.0	(0.36‐2.1) 11	(8.8‐13) 11	(8.3‐13)
AFP	at	diagnosis,	kU/la 360	000	(100	000‐1	200	000)b 59	000	(14	000‐180	000)b 9200	(2600‐32	000) 670	(33‐46	000)
PRETEXT,	n	(%)
I 0	(‐)b 0	(‐)b 1	(20)b 0	(‐)b
II 2	(14) 7	(70) 1	(20) 6	(100)
III 4	(29) 3	(30) 2	(40) 0	(‐)
IV 8	(57) 0	(‐) 1	(20) 0	(‐)
Extrahepatic	disease	at	
diagnosis,	n	(%)
5	(36) 2	(20) 0	(‐) 4	(67)
Local 3	(21) 1 10 0	(‐) 1	(17)
Distant	metastases 2	(14) 1	(10) 0	(‐) 3	(50)
Age	at	surgery,	years 3.9	(2.0‐6.7)b 1.2	(0.69‐2.4)b 12	(9.3‐14) 12	(8.8‐14)
Time	from	diagnosis	to	de‐
finitive	surgery,	months
6.8	(5.0‐13)b 2.4	(1.3‐3.9)b 7.4	(5.9‐7.6) 5.0	(4.7‐5.7)
Follow‐up	time	after	sur‐
gery,	years
8.5	(4.3‐17) 6.5	(2.7‐14) 10	(1.7‐15) 2.6	(0.39‐3.6)
Palliative	resection ‐ 0	(‐) ‐ 4	(67)
Residual	disease	after	definitive	surgery,	n	(%)
Local 0	(‐) 0	(‐) 0	(‐) 2	(33)
Distal 0	(‐) 0	(‐) 0	(‐) 1	(17)
Local	and	distal 0	(‐) 0	(‐) 0	(‐) 1	(17)
Recurrent	disease	after	definitive	surgery,	n	(%)
Local 0	(‐) 0	(‐) 0	(‐) 0	(‐)
Distal 3	(20) 0	(‐) 1	(20) 0	(‐)
Alive	at	last	follow‐up,	n	(%) 9	(64) 10	(100) 4	(80) 1	(17)
Note: P‐values	from	the	Mann‐Whitney	U	test,	Fisher	exact	test,	or	Chi‐square	test	are	reported.
Abbreviations:	AFP,	alpha‐fetoprotein;	HB,	hepatoblastoma;	HCC,	hepatocellular	carcinoma;	LT,	liver	transplantation.
aAFP	missing	for	eight	patients	(HB,	n	=	5;	HCC,	n	=	3).	
bP‐value	<	.05	for	the	difference	between	resection	and	transplantation	subgroups.	
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survival	 was	 80%	 (standard	 error	 8.2%)	 for	 HB	 and	 34%	 (stand‐
ard	 error	14%)	 for	HCC.	Altogether,	 42	patients	 underwent	 surgi‐
cal	management	for	their	malignancy	and	were	included	in	further	
analyses	(Table	1).
Prematurity,	 familial	 adenomatous	 polyposis	 and	 possible	
neonatal	 hemochromatosis,	 according	 to	 earlier	 accepted	 diag‐
nostic	 criteria,	 were	 associated	 disease	 states	 among	 five,	 two	
and	one	patient	with	HB,	respectively.	One	patient	with	chronic	
intrahepatic	 cholestasis	 leading	 cirrhosis	 and	 two	with	 possible	
neonatal	hemochromatosis	had	developed	HCC.	Of	patients	with	
HB,	 eight	 out	 of	 24	 (33%)	 presented	with	PRETEXT	 IV	disease,	
and	apart	from	longer	delay	from	diagnosis	to	definitive	surgery	
(3.9	vs	9.1	months,	P	=	.006)	and	higher	alpha‐fetoprotein	levels	
at	presentation	(400	000	vs	66	000	kU/L,	P	=	 .030),	their	base‐
line	 characteristics	were	 similar	 to	 other	 patients.	 Extrahepatic	
disease	 was	 present	 at	 diagnosis	 in	 four	 patients	 with	 HCC	
(36%)	as	well	 as	 in	 seven	patients	with	HB	 (29%),	of	whom	one	
had	PRETEXT	 I,	 four	PRETEXT	 III	and	 two	PRETEXT	 IV	disease	
(Tables	1	and	2).	Pulmonary	metastases	were	found	in	three	pa‐
tients	 with	 HB	 (13%),	 of	 whom	 two	 had	 PRETEXT	 III	 and	 one	
PRETEXT	 IV	 disease.	 Lung	 metastases	 were	 treated	 with	 che‐
motherapy	 in	 two	 patients	 and	 the	 remaining	 patient	 with	 re‐
section.	None	of	 the	 patients	with	HCC	 fulfilled	 the	University	
of	 California	 of	 San	 Francisco	 or	 the	 Milan	 criteria.19,20	 Apart	
from	one	patient	with	HB	(PRETEXT	II)	who	underwent	upfront	
surgery	 and	 one	 patient	 with	 HCC	managed	 with	 preoperative	
 
All patients, 
n = 42
Transplantation, 
n = 19 Resection, n = 23
Postoperative	complications,	
n(%)
14	(33) 12	(63)b 2	(8.7)b
Relaparotomy	for	bowel	
obstruction/strangulation
2	(4.8) 1	(5.2) 1	(4.3)
Vascular	complications 4	(10) 4	(21) 0	(‐)
Biliary	complications 3	(7.1) 3	(16) 0	(‐)
Intra‐abdominal	infection 3	(7.1) 3	(16) 0	(‐)
Gastrointestinal	bleeding 2	(4.8) 1	(5.2) 1	(4.3)
Age	at	last	follow‐	up	(years) 13	(7.0‐19) 15	(9.0‐27)b 12	(6.2‐15)b
Alive	and	disease‐free	at	last	
follow‐up,	n	(%)
28	(67) 13	(68) 15	(65)
Growth	at	last	follow‐up
Height	(z‐score) ‐0.45	(‐1.0‐1.0) ‐1.0	(‐2.0‐0.50) 0.20	(‐0.70‐1.4)
Weight‐for‐height	(%) 12	(‐3.0‐29) 27	(‐6.0‐40) 5.0	(0.0‐18)
BMI	(for	patients	
aged	>	18	years,	n	=	6)
19	(15‐24) 16	(14‐21) 28	(21‐35)
Disturbed	growtha,	n	(%) 4	(10) 4	(21)b 0	(‐)b
Liver	biochemistry	at	last	follow‐up
AFP,	kU/l 2.0	(1.7‐4.0) 3.0	(2.0‐4.0) 2.0	(1.0‐3.0)
Bilirubin, μmol/l 7.0	(6.0‐17) 14	(7.0‐23) 7.0	(6.0‐10)
ALT,	U/l 23	(17‐42) 34	(19‐41) 23	(16‐48)
Adverse	effects,	n	(%) 16	(38) 10	(53)b 6	(26)b
Transplant	rejection 5	(12) 5	(26) 0	(‐)
Sensorineural	hearing	loss 2	(4.8) 0	(‐) 2	(8.7)
Neuropathy 1	(2.4) 0	(‐) 1	(4.3)
Neutropenia 1	(2.4) 1	(5.2) 0	(‐)
Cardiomyopathy 3	(7.1) 2	(11) 1	(4.3)
ALL 1	(2.4) 0	(‐) 1	(4.3)
AML 2	(4.8) 1	(5.2) 1	(4.3)
Osteoporosis 1	(2.4) 1	(5.2) 0	(‐)
Note: Continuous	data	given	as	median	with	interquartile	ranges.
Abbreviations:	AFP,	alpha‐fetoprotein;	ALL,	acute	lymphoblastic	leukaemia;	ALT,	alanine	transami‐
nase;	AML,	acute	myeloid	leukaemia.
aDisturbed	growth	defined	as	height	<	‐2	z‐scores,	weight‐for‐height	<	‐20%	or	BMI	<	18.	
bP	<	.05	for	the	difference	between	resection	and	LT	subgroups.	
TA B L E  3  Postoperative	complications	
and	follow‐up	characteristics	of	all	
surgically	treated	patients
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transarterial	chemoembolization,	all	others	received	neoadjuvant	
chemotherapy	(Table	1).
3.3 | Surgical management
Primary	 resections	 included	11	 right	hepatic	 lobectomies,	 five	ex‐
tended	right	hepatic	lobectomies,	two	left	hepatic	lobectomies,	one	
extended	 left	 lobectomy	 and	one	 left	 lateral	 segmentectomy	 (left	
trisegmentectomy).	 Patients	 with	 HB	 and	 HCC	 underwent	 liver	
transplantation	 or	 resection	 with	 relatively	 similar	 frequencies,	
while	 all	 patients	 with	 undifferentiated	 embryonal	 sarcoma	 were	
managed	 with	 liver	 resection	 (Table	 2).	 Patients	 who	 underwent	
liver	transplantation	had	a	significantly	longer	delay	from	diagnosis	
to	definitive	surgery	 (Table	2).	Six	patients	underwent	rescue	 liver	
transplantation	6.0	(4.8‐11)	months	after	primary	tumour	resection	
(Table	S1).	Baseline	characteristics,	postoperative	complications	and	
recurrence	 rates	 were	 comparable	 after	 primary	 and	 rescue	 liver	
transplantation	 (p	 =	 ns	 for	 all).	 Surgical	 complications	 were	 more	
common	after	liver	transplantation	than	resection	(Table	3).	Vascular	
complications	occurred	in	four	patients,	two	of	whom	had	a	throm‐
bosis	of	the	hepatic	artery	while	two	a	portal	vein	stenosis	(Table	3).	
One	retransplantation	was	performed	due	to	arterial	thrombosis.
F I G U R E  1  The	cumulative	survival	
of	surgically	treated	hepatoblastoma	
patients	according	to	PRETEXT	stage,	
type	of	surgery	and	recurrence.	LT,	liver	
transplantation.	P‐values	from	the	log‐
rank	test	are	reported
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TA B L E  4  Univariate	analysis	of	5‐year	Kaplan‐Meier	overall	survival	of	surgically	treated	hepatoblastoma	patients	after	liver	malignancy	
diagnosis
Univariate
HB patients (n = 24)
Patients (n)
5‐year survival, %, 
mean (SE) P‐value Patients (n)
5‐year disease‐free sur‐
vival, %, mean (SE) P‐value
Management	before	2005
Yes 11 91	(9.0) .817 11 79	(13) .683
No 13 76	(16) 13 65	(18)
Age	at	diagnosisa,b
<High‐risk	age 21 88	(8.0) .090 21 81	(10) .290
≥High‐risk	age 3 67	(27) 3 33	(27)
Age	at	surgeryc
<2.4	years 12 100	(‐) .040 12 76	(15) .121
≥2.4	years 12 73	(13) 12 56	(15)
PRETEXT
I 0 ‐ .004 0 ‐ <.001
II 9 100	(‐) 9 100	(‐)
III 7 100	(‐) 7 100	(‐)
IV 8 60	(18) 8 31	(18)
Histologyd
Low	risk 9 76	(15) .460 9 76	(15) .926
Intermediate	risk 11 100	(‐) 11 63	(21)
High	risk 3 67	(27) 3 67	(27)
Vascular	invasion
Yes 17 80	(11) .490 17 58	(14) .327
No 7 100	(‐) 7 80	(18)
Extrahepatic	disease	at	diagnosis
Yes 7 100	(‐) .162 7 80	(18) .573
No 17 80	(12) 17 70	(13)
Risk	levela
Very	low 0 ‐ .552 0 ‐ .126
Low 2 100	(‐) 2 100	(‐)
Intermediate 10 83	(15) 10 83	(15)
High 11 81	(12) 11 56	(17)
Surgical	management
LT 9 76	(15) .265 9 65	(17) .067
Rescue	LT 5 80	(18) 5 38	(29)
Resection 10 100	(‐) 10 100	(‐)
Delay	from	diagnosis	to	definitive	surgerye
<4.9	months 12 100	(‐) .054 12 88	(11) .096
≥4.9	months 12 74	(13) 12 61	(15)
Any	surgical	complications
Yes 6 83	(15) .184 6 67	(19) .886
No 18 85	(10) 18 76	(13)
Recurrent/residual	disease	after	surgery
Yes 3 67	(27) .029 3 0	(‐) <.001
No 21 88	(8.0) 21 87	(9.0)
Note: P‐values	from	the	log‐rank	test	are	reported.
Abbreviations:	AFP,	alpha‐fetoprotein;	HB,	hepatoblastoma;	LT,	liver	transplantation;	SE,	standard	error;	SCU,	small	cell	undifferentiated.
aMeyers	RL,	Maibach	R,	Hiyama	E,	et	al.	Risk‐stratified	staging	in	paediatric	hepatoblastoma:	a	unified	analysis	from	the	Children's	Hepatic	Tumors	
International	Collaboration.	Lancet	Oncol	2017;18(1):122‐131.	
bHigh‐risk	age	at	diagnosis	according	to	PRETEXT	group	(>3	years	for	PRETEXT	IV	and	>	8	years	for	PRETEXT	I‐III).	
cMedian	age	at	surgery	2.4	(1.7‐4.9)	years.	
dLow	risk	defined	as	foetal	histology,	high‐risk	as	small	cell	undifferentiated,	and	intermediate	as	other	histology.	
eMedian	delay	from	diagnosis	to	surgery	4.9	(2.7‐8.9)	months.	
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3.4 | Outcomes of hepatoblastoma
Cumulative	 overall	 5‐year	 survival	 for	 operated	 patients	 with	 HB	
was	86%	(standard	error	7.8%)	and	5‐year	disease‐free	survival	73%	
(standard	error	11%).	All	patients	with	PRETEXT	II	and	III	survived,	
whereas	 the	cumulative	5‐year	 survival	 for	PRETEXT	 IV	was	60%	
(Figure	 1).	 Five	 out	 of	 the	 14	 transplanted	 patients	 with	 HB	 had	
undergone	 rescue	 liver	 transplantation	 either	 because	 of	 residual	
disease	 or	 recurrence	 after	 resection	 (Table	 S1).	 Three	 patients	
with	HB,	all	with	PRETEXT	 IV,	developed	distant	 recurrence	after	
liver	transplantation	and	had	a	 lower	5‐year	survival	 than	patients	
without	recurrent	disease	(Table	4,	Figure	1).	Recurrent	HB	metas‐
tases	were	managed	with	 chemotherapy	 in	 one	patient,	 resection	
in	 one	 patient	 or	 by	 both	 in	 one	 patient.	Disease	 recurrence	was	
successfully	 managed	 in	 both	 patients	 with	 familial	 adenomatous	
polyposis	who	are	alive	17	and	25	years	after	liver	transplantation.	
Causes	of	death	were	recurrence	in	two	patients,	leukaemia	in	one	
patient,	septic	infection	in	one	patient	and	suicide	in	one	patient	(age	
19	years).	PRETEXT	 IV	disease,	age	over	2.4	years	at	surgery,	and	
recurrence	associated	with	decreased	survival,	while	patients	with	a	
shorter	delay	from	diagnosis	to	definitive	surgery	tended	to	survive	
longer	(Table	4).
3.5 | Outcomes of hepatocellular carcinoma
Five‐year	overall	survival	for	operated	patients	with	HCC	was	41%	
(standard	 error	 16%).	 The	 only	 factor	 predicting	 decreased	 sur‐
vival	 for	HCC	was	 recurrent	or	 residual	disease	 (0%	versus	83%,	
standard	 error	 15%,	P	 =	 .028),	whereas	 other	 patient	 character‐
istics	 such	 as	 histology,	 PRETEXT	 stage	 and	 age	were	 unrelated	
with	survival	(Figure	2).	Four	patients	with	disseminated	HCC	un‐
derwent	a	planned	palliative	resection.	The	patient	with	PRETEXT	
stage	 I	 HCC	 and	 underlying	 cirrhosis	 due	 to	 neonatal	 hepatitis	
underwent	 a	primary	 liver	 transplantation.	Residual	 extrahepatic	
disease	 in	 patients	who	 had	 undergone	 palliative	 liver	 resection	
was	managed	with	chemotherapy	in	three	patients	and	redo	liver	
resection	in	one	patient,	while	recurrent	HCC	after	liver	transplan‐
tation	in	one	patient	was	managed	with	chemotherapy.	However,	
none	of	 the	patients	with	 recurrent/residual	disease	survived.	 In	
addition,	one	patient	with	HCC	died	of	cardiomyopathy	after	suc‐
cessful	resection.
3.6 | Outcomes of embryonal carcinoma
Seven	patients	with	undifferentiated	embryonal	sarcoma	presented	
with	PRETEXT	stage	II	or	III	disease.	Of	them,	two	had	extrahepatic	
disease	 at	 diagnosis	 and	 all	 were	managed	with	 liver	 resection	 at	
median	age	of	5.6	years	(Table	1).	Both	cumulative	overall	survival	
and	disease‐free	survival	were	67%	(standard	error	19%)	at	5	years.	
One	patient	developed	pulmonary	 recurrence	and	eventually	died	
despite	lung	resection.	Two	other	patients	with	undifferentiated	em‐
bryonal	sarcoma	died	of	leukaemia	disease‐free,	diagnosed	1.1	and	
7.1	years	after	successful	liver	resection.
3.7 | Follow‐up patient characteristics
Overall,	 by	 the	end	of	 the	 follow‐up	at	median	age	of	12.6	years,	
28/42	patients	 (67%)	were	alive	and	disease‐free	 (Table	3).	Out	of	
the	14	patients	who	died	during	follow‐up,	eight	died	of	recurrent	
or	residual	primary	liver	malignancy,	three	of	leukaemia,	one	of	car‐
diomyopathy,	one	of	septic	infection	and	one	as	disease‐free	of	sui‐
cide	(age	19	years).	At	the	latest	follow‐up	visit,	four	patients	(9.5%)	
had	disturbed	growth	(defined	as	height	<	‐2.0	z‐scores,	weight‐for‐
height	<	‐20%,	or	BMI	<	18),	of	whom	two	had	familial	adenomatous	
polyposis,	 three	had	been	 successfully	 treated	 for	 recurrence	 and	
one	later	died	of	disease	recurrence	(Table	3).	Other	adverse	effects	
of	chemotherapy,	including	sensorineural	hearing	loss,	neuropathy,	
neutropenia	and	cardiomyopathy,	were	detected	 in	seven	patients	
(17%).	One	patient	 (2.4%)	diagnosed	with	chronic	rejection	had	el‐
evated	ALT	and	bilirubin	levels.
4  | DISCUSSION
This	study	entailed	all	patients	treated	 in	one	country	from	an	era	
(1987‐2016)	when	liver	transplantation	was	available	and	represents	
one	of	the	 longest	follow‐ups	on	paediatric	 liver	malignancies.21,22 
Centralised	management	of	paediatric	liver	cancer	and	use	of	accu‐
rate	national	registry	data	enabled	reliable	calculation	of	incidence,	
recurrence	 and	 survival	 rates	 as	well	 as	 a	 detailed,	 long‐term	 and	
complete	 patient	 follow‐up.	 Our	 findings	 show	 encouraging	 long‐
term	survival	 for	HB	excluding	patients	with	PRETEXT	 IV	disease,	
which	 associated	with	 complications	of	 chemotherapy,	 recurrence	
and	decreased	survival	in	the	long‐term.
The	 incidence	of	HB	 is	 increasing	 in	 the	United	States	 and	 al‐
though	 an	 increase	 was	 also	 observed	 in	 Europe	 between	 1970s	
and	1990s,	 no	 similar	 trend	 exists	 in	more	 recent	 epidemiological	
studies.13,23,24	 Accordingly,	 our	 results	 demonstrate	 steady	 inci‐
dence	rates	of	1.1:106	for	paediatric	liver	malignancies	and	0.66:106 
for	HB	over	a	30‐year	 time	period,	 corresponding	a	 slightly	 lower	
incidence	for	HB	while	higher	for	HCC	when	compared	with	previ‐
ously	 reported	European	numbers.24	Cancer	 incidence	 among	 the	
first‐degree	relatives	of	liver	malignancy	patients	was	similar	to	con‐
trols,	supporting	the	concept	that	most	paediatric	liver	malignancies	
are	explained	by	other	factors	than	inherited	conditions.1	Whether	
the	three	patients	with	possible	neonatal	hemochromatosis,	accord‐
ing	to	earlier	accepted	diagnostic	criteria,	who	developed	liver	ma‐
lignancy	actually	had	gestational	 alloimmune	 liver	disease	 remains	
unclear.	Although	young	age	at	diagnosis	associated	with	improved	
outcomes	for	HB,	possibly	due	to	the	small	sample	size,	the	previ‐
ously	suggested	age	or	alpha‐fetoprotein	cut‐offs	were	insignificant	
among	our	patients.2
The	observed	5‐year	overall	survival	of	86%	for	HB	in	the	pres‐
ent	study	was	similar	to	most	recent	reports.3	However,	while	both	
overall	 and	disease‐free	 long‐term	survival	was	100%	 for	patients	
presenting	with	 lower	PRETEXT	stages,	 the	survival	outcomes	 for	
PRETEXT	 IV	 HB	 were	 markedly	 inferior	 although	 comparable	 to	
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larger	 contemporary	 reports.2,22	 As	many	 as	 one‐third	 of	 our	 pa‐
tients	with	HB	presented	with	either	PRETEXT	 IV	or	extrahepatic	
disease,	clearly	exceeding	the	proportions	of	such	high‐risk	patients	
in	 most	 large	 HB	 series.2,3,9	 One	 factor	 possibly	 contributing	 to	
suboptimal	outcomes	for	PRETEXT	IV	HB	may	be	the	longer	delay	
from	diagnosis	to	definitive	surgery	compared	with	lower	PRETEXT	
stages,	leading	to	increased	exposure	to	chemotherapy22; however, 
this	was	not	a	statistically	significant	predictor	of	survival.	The	me‐
dian	delay	of	7	months	from	diagnosis	to	 liver	transplantation	was	
similar	 than	 previously	 reported	 in	 the	 United	 States;	 however,	
considerably	better	HB	survival	has	been	reported	after	very	short	
transplant	waiting	list	times.22	In	Finland,	no	living‐donor	liver	trans‐
plantation	is	currently	performed,	influencing	transplant	list	waiting	
times	and	cumulative	chemotherapy	exposure.	The	need	for	rescue	
liver	transplantation	in	five	patients	with	HB	also	contributed	to	in‐
creased	chemotherapy	exposure.
Although	the	41%	5‐year	survival	for	HCC	is	dismal,	it	compares	
favourably	to	larger	studies	including	similar	proportions	of	patients	
with	metastatic	disease.5,6	Likely	due	to	the	small	number	of	patients	
with	 HCC,	 no	 statistically	 significant	 predictors	 of	 survival	 apart	
from	recurrent	and	residual	disease	were	 identified.	Nevertheless,	
only	one	 liver	 transplantation	 recipient	with	HCC	experienced	 re‐
currence	 and	 died,	 supporting	 the	 benefit	 of	 liver	 transplantation	
for	children	with	inoperable	HCC	without	extrahepatic	involvement	
even	when	the	Milan	or	University	of	California	of	San	Francisco	cri‐
teria	 are	 not	 fulfilled.25	Metastatic	HCC,	 instead,	 remains	 a	major	
challenge	and	was	the	main	cause	of	mortality	also	among	most	of	
our	patients	with	HCC.	While	regular	screening	of	children	with	in‐
herited	liver	diseases	may	help	to	detect	HCC	in	time,	sporadic	liver	
malignancies	presenting	with	vague,	nonspecific	symptoms	are	sel‐
dom	detected	 in	early	stage.4,5	Promisingly,	novel	treatments	such	
as	sorafenib	and	transarterial	chemoembolization	may	both	improve	
tumour	resectability	and	decrease	postoperative	recurrence	rates.26 
Such	management	options	emerged	at	the	end	of	our	30‐year	fol‐
low‐up,	and	 larger	cohorts	are	needed	 to	evaluate	 their	benefit	 in	
paediatric	HCC.
F I G U R E  2  The	cumulative	survival	
of	surgically	treated	hepatocellular	
carcinoma	patients	according	to	type	of	
surgery,	and	recurrence/residual	disease.	
LT,	liver	transplantation.	P‐values	from	the	
log‐rank	test	are	reported
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Our	 overall	 postoperative	 complication	 rate	 of	 33%	was	 com‐
parable	 with	 previous	 studies.21	 Any	 vascular	 complications,	 oc‐
curring	in	one‐fifth	of	our	patients	after	liver	transplantation,	have	
been	previously	reported	to	affect	up	to	25%‐40%	of	paediatric	liver	
transplantation	recipients	and	to	be	more	common	in	patients	trans‐
planted	 for	 malignant	 than	 benign	 conditions.21,22	 In	 the	 present	
series,	 only	one	patient	was	 retransplanted	due	 to	 arterial	 throm‐
bosis	leading	to	biliary	necrosis.	Despite	the	low	rate	of	severe	op‐
erative	 complications,	 over	 one‐third	 of	 all	 deceased	 patients	 and	
half	of	deceased	patients	with	HB	died	of	adverse	effects	related	to	
chemotherapy	 or	 immunosuppression.	 Secondary	 cancer,	 possibly	
induced	by	the	use	of	alkylating	agents,	also	contributes	to	our	mod‐
est	5‐year	survival	of	67%	for	undifferentiated	embryonal	sarcoma.7 
Since	 toxicity	 of	 cisplatin,	 anthracyclines	 and	 alkylating	 agents	 is	
dose‐dependent,	lower	overall	exposure	to	chemotherapy	could	re‐
duce	their	severe	side	effects.27‐29	Long‐term	survival	could	increase	
by	improving	patient	selection	for	primary	liver	transplantation	and	
the	 timely	 availability	 of	 optimal	 transplants	 thereby	 reducing	 the	
need	for	preoperative	chemotherapy22.	The	latest	rescue	liver	trans‐
plantation	for	residual	malignancy	in	our	centre	was	performed	more	
than	a	decade	ago.
The	 main	 limitations	 of	 this	 study	 included	 our	 inability	 to	
record	 reliably	 the	 exact	 cumulative	 dosage	 of	 chemotherapy,	
the	 low	number	 of	 patients	 due	 to	 rarity	 of	 childhood	 liver	ma‐
lignancies	 and	 the	 various	 chemotherapy	 protocols	 and	 surgical	
approaches	applied	during	the	long	study	period.	During	the	last	
decade,	PRETEXT	IV	patients	have	undergone	primary	LT	instead	
of	tumour	resection.
5  | CONCLUSIONS
Apart	 from	PRETEXT	 IV	disease,	 the	national	 outcomes	 for	 sur‐
gically	 treated	 HB	 are	 encouraging.	 Outcomes	 of	 HCC	 and	 un‐
differentiated	embryonal	 sarcoma	are	 largely	determined	by	 the	
presence	of	extrahepatic	disease.	Diagnosing	paediatric	liver	ma‐
lignancies	at	earlier	stage	as	well	as	reducing	exposure	to	chemo‐
therapy	 appears	 challenging	 but	 attainable	 means	 to	 improve	
survival.
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